---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093345"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:03:12.875582+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma Q2 net loss $1.2M on $16.2M tax benefit; cash $212.9M; PYNNACLE Phase 2 on track

## Summary
- Net loss narrowed to $1.2M from $17.4M YoY due to $16.2M income tax benefit from NOL sale.
- Cash, equivalents, and marketable securities $212.9M; net cash used in operations $17.8M in H1 2024.
- Phase 2 monotherapy enrollment on track; >60% sites activated; interim analysis expected by mid-2025.
- Phase 1b rezatapopt/pembrolizumab combo adjusted to exclude KRAS SNV; DLTs observed at 1000 mg, then escalated back.
- Lease termination at Princeton HQ with $1.42M fee; relocation to smaller space to reduce costs.

## SEC filing metadata
- accession: 0000950170-24-093345
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.02, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000095017024093345/0000950170-24-093345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000095017024093345/pmvp-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093345
- JSON: https://secwatch.observer/filing/0000950170-24-093345.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093345.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.